Effects of Dapagliflozin in Chronic Kidney Disease Across the Spectrum of Age and by Sex.

ABSTRACT:

Background

The sodium-glucose cotransporter type 2 inhibitor dapagliflozin reduces the risk of progressive kidney disease and cardiovascular events in patients with chronic kidney disease, with and without type 2 diabetes. Whether its effects are uniform across the spectrum of age and among men and women is unknown.

Objective

We performed a pre-specified analysis in DAPA-CKD to evaluate efficacy and safety of dapagliflozin according to baseline age and sex.

Design

Prospective randomized placebo-controlled trial.

Participants

A total of 4304 adults with chronic kidney disease (estimated glomerular filtration rate (eGFR) 25-75 mL/min/1.73 m²; urinary albumin-to-creatinine ratio 200-5000 mg/g) with and without type 2 diabetes.

Intervention

Dapagl

SUBMITTER: Yu MK 

PROVIDER: S-EPMC11074069 | biostudies-literature | 2024 May

REPOSITORIES: biostudies-literature